


PAR-1 on the Astrocyte End Foot: A New Target for Pharmacological Intervention in Neurological Diseases

התערבות פרמקולוגית
ייחודית במסלול הפעלת
הרצפטור לתרומבין – בסיס
חדש לטיפול בפגיעה עצבית


Joab Chapman, Efrat Shavit.

PAR: Protease-Activated Receptor







Development of novel PAR-1-based therapeutic compounds for neuro-inflammatory and malignant diseases: diabetic neuropathy and glioblastoma multiforme




The Neuron

The functional unit of the nervous system







Scheme of Astrocyte with Neuron




Motor Neuron in Cell Culture



Astrocyte in Brain with Neurons






Glial endfeet at synapse and node of Ranvier






Development of novel PAR-1-based therapeutic compounds for neuro-inflammatory and malignant diseases: diabetic neuropathy and glioblastoma multiforme


- The thrombin receptor PAR-1 (protease activated receptor) is found mainly on astrocytes
- We have found PAR-1 both at the synapse and node of Ranvier



Shavit et al. J neurochem 2011




Shavit et al. Brain 2008





Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block




Shavit et al. *Brain*.2008




PAR1 activation by independent proteases




PAR-1 physiological/pathophysiological role



Thrombin-like activity in brain




Thrombin Activity in Ischemic vs. Healthy Brains





■ 24h following MCA

■ Each group n=6

Thrombin like activity in brain slices




Significant elevated thrombin-like activity in disease models involving the peripheral nervous system





Aronovich et al. (submitted) Abu Rahal et al. (submitted)







PAR-1 (red) Astrocytes (green) in cerebellum of Wild Type Mice






PAR-1 in Frontal Brain of SOD ALS Mouse Model






PAR1 activation by independent proteases

PAR-1 physiological/pathophysiological role





Thrombin inhibition (specific and general) significantly improves nerve-conduction and survival in neuroinflammation-involved diseases





Increased PAR-1 level in glioma cells



FCS free




FCS



Development of novel PAR-1-based therapeutic compounds for neuro-inflammatory and malignant diseases: diabetic neuropathy and glioblastoma multiforme



Thrombin-like activity is generated by glioma cell-lines




PAR-1 pathway modulation inhibits glioma-cells proliferation



PAR1 activation by independent proteases


PAR-1 physiological/pathophysiological role




Existing drugs may not be ideal

- Do not cross blood brain barrier
- Toxic to normal brain function
- Intrinsically inhibit coagulation
- Block one pathway only (e.g. PAR-1 /Par-4)
- May miss specific brain disease targets
- Pose complex IP issues

General Strategy Outline



Disease targets: Outline



Targeting central and peripheral nervous system diseases

Internal


- ▣ Autoimmune (GBS)
- ▣ Neoplastic (GBM)
- ▣ Neurodegenerative (ALS)
- ▣ Diabetic neuropathy
- ▣ Epilepsy (Generation)

External



- ▣ ICH/Stroke
- ▣ Trauma
- ▣ Infection
- ▣ Metabolic (Diabetes)
- ▣ Epilepsy (Symptom)

Targets in the PAR-1 activation pathway: protease based approaches

- Identity of protease (thrombin/trypsin)
- Synthesis (Vit K)
- Release
- Activation (cascade)
- Endogenous inhibitors
- Docking at PAR-1



שרשרת הקרישה מה שמקובל



The group

